Stratifying IC/BPS patients based on the prevalence of exhausted CD8 + T cells could facilitate the design of targeted clinical trials and identify those most likely to benefit from immunotherapeutic interventions. The gene discussed is CD8A; the disease is Bartsocas-Papas syndrome 1.